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Abstract
Background:  Gastric adenocarcinoma is one of the most frequent malignancies worldwide
including Iran. This study was designed to immunohistochemically evaluate the CD117 and bcl-2
expression in gastric carcinomas and their potential use as therapeutic targets in the treatment of
patients with advanced stage gastric cancer.
Materials and methods: Representative paraffin blocks obtained from 38 operated gastric
adenocarcinoma patients were retrieved from Afzalipour Hospital pathology department archive,
Kerman, Iran. Immunohistochemical analysis (IHC) for CD117 was carried out in all cases including
negative (normal gastric epithelium) and positive (Gastrointestinal Stromal Tumor) controls. In
addition, the cases were evaluated immunohistochemically for apoptosis-related protein (bcl-2), to
evaluating a potential association of CD117 expression with the cell proliferation regulatory
pathways.
Results: No positive reaction for CD117 was seen in gastric carcinoma tumor cells irrespective
to the cell type, grade, and stage, proliferation and apoptosis rate. Expression of bcl-2 was observed
in only one case.
Conclusion: We conclude that CD117 overexpression detectable by immunohistochemistry
does not play a significant role in gastric carcinoma pathways and development, although
overexpression at the gene level and/or mutated CD117 expression might exist. Thus, it is unlikely
that the CD117 pathway is of clinical significance in gastric carcinoma patients.
Background
Gastric carcinoma is the second most frequent malig-
nancy in the world constituting about 10% of newly diag-
nosed malignancies and accounting for more than 12% of
cancer deaths [8]. It is the disease of the elderly with a
median age of 72 years in American patients at the time of
diagnosis [8]. Immunohistochemically (IHC), almost all
tumors are positive for cytokeratin and epithelial mem-
brane antigen [43]. Furthermore, gastric carcinomas have
been shown to be positive for following factors in differ-
ent proportions: Pancreatic Secretory Trypsin Inhibitor
(76% and 89% in intestinal and diffuse types respectively)
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[19], carcinoembryonic antigen (30–55 %), Villin (47 %),
Beta Catenin (63%), CD44 (55–58%), [22,43] and Pla-
cental Alkaline Phosphatase (23%) [49]. Mutations of the
p53 protein and abnormalities of the Adenomatous Poly-
posis Coli (APC) gene were found in about 50% of cases
[1]. In the literature, only one study examining the expres-
sion of CD117 in gastric carcinomas exists to our knowl-
edge until now [18]. This study reports an expression of
the protooncogene c-kit and its ligand stem cell factor
(SCF) in gastric carcinoma cell lines [18]. In vivo, the
potential expression of the protein in human gastric carci-
noma has not been analyzed, and no statement about the
potential clinical significance of the in vitro study has
been given to our knowledge.
Classically gastric carcinomas are classified to intestinal
and diffuse type according to the Lauren classification
[29]. Although the role of adjuvant therapies in advanced
gastric cancer is under debate, generally surgical resection
is considered as the standard therapy and response to
other methods of treatment is poor [46].
Gastric carcinomas are usually detected at advanced
tumor stages. The factors involving the miss an early diag-
nosis comprise anatomical and clinical reasons. Anatom-
ically, the stomach has a very large luminal space and the
tumors can reach quite a large size prior to inducing pain
or symptoms of obstruction. From the clinical point of
view, symptoms of gastric carcinoma are equivalent to
benign lesions such as chronic gastritis or peptic ulcer.
Often, these lately diagnosed tumors are no longer ame-
nable to surgery. Population based gastric cancer screen-
ing programs have not been implemented in most
countries due to lack of sensitive and specific serum tumor
markers, high economic burden, and poor compliance of
routine gastroscopy.
Thus, it seems reasonable to investigate in new therapeu-
tic modalities for advanced gastric cancer. Immunotarget-
ing and blocking specific tumor growth pathways is one of
the new promising strategies. Successful examples include
regimes against CD20 and Her-2-neu in non-Hodgkin's B
cell lymphoma (NHL) and advanced stage breast carci-
noma, respectively [5,23]. Chimeric anti-CD20 antibody
(rituximab) sensitizes B cells in NHL to inducing apopto-
sis by cytotoxic substances, for example, by diminishing
the Bcl-x expression [23]. Inhibitor of Her-2-neu protein
(trastuzumab) has been reported to induce a 19%
response rate in metastatic breast carcinoma patients [5].
An additional agent is associated with the expression and
inhibition of CD117 (c-kit), and has been effectively used
in various neoplasms such as hematological malignancies
and gastrointestinal stromal tumors (GIST). Thus, these
inhibitors could be potentially considered as a new target
for therapeutic regimes in gastric carcinomas; however,
only if a significant CD117 expression could be demon-
strated, i.e., by use of IHC.
Expression of CD117, c-kit and the stem cell factor (SCF) 
receptor
CD117 is coded by the c-kit protooncogene on chromo-
some 4q11-q12 [42]. Being a cell surface protein it is cat-
egorized into the third variety of cell receptors named
receptors with intrinsic kinas activity [10]. It possesses three
domains of extra cellular, intracellular, and transmem-
brane location. Related receptors include the granulocyte
colony stimulating factor (G-CSFR) and platelet derived
growth factor (PDGFR). The extra cellular domain pos-
sesses five immunoglobulin-like areas. The first three are
responsible for binding with stem cell factor (SCF). Fol-
lowing a complex formation with SCF the intracellular
domain is phosphorylated and new sites are provided for
cytoplasmatic messengers e.g. IP3, Src, and ras. Following
these events, the cell is committed for entering the S phase
and cell proliferation cycle [30].
The expression of the CD117 protein has been identified
in different cells types, such as osteoclasts, Langerhans
cells, cord blood cell, renal tubules epithelial cells, sweat
gland cells, or megakaryocytes [3]. It probably plays a
physiologic role in the proliferation of these cells. A signif-
icant influence of C-kit in the formation and growth of
extremities at embryonic stages has been suspected by ani-
mal model studies [41]. Mast cells are dependent on the
autocrine circle of CD117 [1], and the loss of CD117 in
germinal cells of embryonic testis results in an increased
apoptosis of germ cells and infertility in the following life
periods [13]. Soluble c-kit can mobilize bone marrow
cells into the peripheral blood via the interaction with the
vascular cell adhesion molecule 2 (VCAM-2) [35]. Both,
SCF and CD117 take influence on the growth of endothe-
lial cells and smooth muscle cells of the umbilical vein
[33]. However, the main function of CD117 is the activa-
tion of the cell proliferation. Expression of CD117 has
been noted in a subset of angiosarcoma cases, a phenom-
Table 1: Immunohistochemical detection of CD117 in malignant 
tumors
Tumor Type Reactivity 
(%)
Number of 
cases studied
Endometrial carcinoma 100 8
Follicular carcinoma of thyroid 100 11
Papillary carcinoma of thyroid 100 9
Merkel cell carcinoma 96 22
Seminoma 96 65
Ovarian serous cystadenocarcinoma 94 16
Renal cell carcinoma, chromophobe 90 74
Osteogenic sarcoma 84 18Diagnostic Pathology 2006, 1:7 http://www.diagnosticpathology.org/content/1/1/7
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enon that has been compared to the action of an oncofetal
protein or its anti-apoptotic effect [9].
In man, CD117 proto-oncogene mutations result in an
autosomal dominant disease named piebaldism [24].
Somatic mutations have been recorded in various tumor
cell types. The mutation of the c-kit protooncogene has
been frequently observed in germ cell tumors, particularly
in seminoma [25].
Although an over-expression of CD117 mRNA was noted
in cell lines of malignant fibrous histiocytomas [36], IHC
evaluation of such tumors for c-kit revealed only one pos-
itive reaction out of 43 cases [51]. Immunohistochemi-
cally, expression of CD117 also has been demonstrated in
leiomyosarcomas of the uterus [39], and has been identi-
fied in about 50% of small cell or large cell neuroendo-
crine lung carcinomas [2]. Over-expression of CD117 is
almost always seen in GIST [42]. Immunohistochemi-
cally, its expression usually serves for diagnostic differen-
tiation of these tumors from morphologically similar
neoplasms [15]. Singular CD117 expression or in combi-
nation with that of SCF is noted in several hematopoetic
tumors including mast cell leukemia, acute myelogenous
leukemia, and other myeloproliferative disorders [10]. In
fact, the c-kit expression in acute leukemia can be consid-
ered as an indicator of myeloid origin of tumor cells [10]
as it is rarely expressed in lymphoid blast cells. Meanwhile
Table 2: Details of demographic, microscopic, pathologic and immunohistochemical findings in the study cases
Ser. No. Sex Age Year of 
Operation
Location Cell Type Grade Stage
1F5 0 1 9 9 9 AD -I I I B
2F4 8 1 9 9 9 D I D -I V
3M 7 0 1 9 9 9 BD -I I I A
4 F 65 1999 A I PD IIIA
5M 5 8 1 9 9 9 AD -I I I A
6 M 59 1999 DI D - IIIA
7 M 75 1999 B I MD IIIA
8M 2 8 2 0 0 0 AD -I I I B
9M 6 5 2 0 0 0 AD -I I
10 F 65 2000 A I WD IIIB
11 F 54 2001 A D - IIIA
12 M 70 2001 B I PD IIIA
13 M 70 2001 C D IV
14 M 45 2001 C, B I PD IIIB
15 M 60 2001 A I MD II
16 M 51 2001 A I MD IIIB
17 F 67 2001 B D - IIIB
18 F 67 2002 C D - IIIB
19 M 39 2002 C I WD IIIA
20 F 79 2002 B I MD IIIA
21 F 44 2002 DI D - IIIA
22 M 63 2002 A I WD IB
23 M 48 2002 A I PD IIIB
24 M 52 2002 DI D - IIIB
25 M 68 2002 A I WD II
26 M 70 2002 A I WD IIIA
27 M 88 2002 A I PD IIIA
28 F 30 2003 C I MD IIIA
29 M 53 2003 C I WD IB
30 F 53 2003 C I MD IIIB
31 F 60 2003 - I PD IIIB
32 F 48 2003 A D IIIB
33 M 42 2003 A Mucinous WD IIIA
34 M 65 2003 B D - IIIB
35 M 45 2003 DI D - IIIA
36 M 23 2003 GEJ I WD IIIA
37 M 58 2003 A D - IIIB
38 F 35 2003 A I PD IIIB
Abbreviations: M: male; F: female; A: antral; B: body; C: cardia; DI: diffuse infiltrative; GEJ: gastro-esophageal junction; D: diffuse type; I: intestinal 
type; PD: poorly differentiated; MD: moderately differentiated; WD: well differentiated.Diagnostic Pathology 2006, 1:7 http://www.diagnosticpathology.org/content/1/1/7
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its expression in myeloid cells forms the basis for detect-
ing a minimal residual disease (MRD) by flow cytometry
[10]. Most tumor cells in Hodgkin's disease including
mononuclear and Reed-Sternberg cells express c-kit [10].
Colon carcinomas rarely display a positive cytoplasmatic
reaction for CD117 by IHC [40]. C-kit expression varies to
a great extent in soft tissue sarcomas, and ranges from
10% in myxoid sarcomas to 60% in melanocytic schwan-
nomas [21]. In human gliomas c-kit is widely expressed
and an autocrine pathway of tumor activation and pro-
gression by c-kit and its ligand has been suggested herein
[17]. Interestingly, normal breast epithelial cells abun-
dantly express c-kit, whereas a loss of c-kit expression has
been reported in 80–90% of breast cancer cases [37]. In
vitro, the transfer of the c-kit gene into a breast cancer cell
line resulted in the suppression of cellular growth [37].
These observations suggest an inhibitory effect of c-kit and
its ligand in breast cancer proliferation. One study reports
a co expression of c-kit and stem cell factor genes in breast
carcinoma and a possible autocrine activation of these
cancer cells [20]. A survey of malignant tumors with posi-
tive CD117 immunohistochemical reactivity is listed in
table 1 according to [22].
Inhibitors of c-kit
Some endogenous cytokines have shown to posses inhib-
itory effects on the c-kit receptor [6,28]. Such endogenous
inhibitors including TGFβ1 and IL4 were successfully
applied in experimental animals and in colon carcinoma
cell lines [6,28]. One of the protein tyrosine kinase inhib-
itors, SU5614 can induce cellular growth arrest and apop-
tosis in AML by inhibiting the c-kit receptor [45]. STI571
or Imatinib Mesylate is another molecule representing the
exogenous inhibitor. Originally applied for the treatment
of CML by inhibiting 9;22 the translocation induced tyro-
sine kinase [44], it later served for an effective treatment of
a variety of malignancies including metastasizing gas-
trointestinal stromal tumors [12]. The treatment with c-kit
inhibitors in 21 patients with AML who were partly resist-
ant to chemotherapy was promising too [27]. In vitro
studies of small cell lung carcinoma cell lines showed a
synergistic effect for c-kit and IGF-1R inhibitors in the
induction of apoptosis [9,48]. Other in vitro studies dis-
Negative immunohistochemical reaction for CD117 in gastric  carcinoma tumor cells Figure 3
Negative immunohistochemical reaction for CD117 in gastric 
carcinoma tumor cells.
H&E appearance of intestinal type gastric cancer Figure 1
H&E appearance of intestinal type gastric cancer.
H&E appearance of diffuse type gastric cancer Figure 2
H&E appearance of diffuse type gastric cancer.Diagnostic Pathology 2006, 1:7 http://www.diagnosticpathology.org/content/1/1/7
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played an inhibition of cell proliferation and induction of
apoptosis in colon carcinoma [4], breast carcinoma [37],
Ewing sarcoma [16] and neuroblastoma cell lines [7]. In
addition, a successfully treated case suffering from a hepa-
tocellular carcinoma and liver cirrhosis has been
described [38].
Bcl-2 protein
Bcl-2 protein is a 26 Kd protein with the major role in con-
trolling apoptosis. Bcl-2 production is controlled by a
gene located on chromosome 18 [14]. Bcl-2 belongs to a
family of proteins which includes Bax protein [31]. Bax
counteracts the effects of bcl-2 by increasing cell suscepti-
bility to apoptotic stimuli [31]. In fact it is appeared that
the ratio of bcl-2 to Bax proteins control the sensitivity or
resistance of many cell types to apoptotic stimuli [31].
Although the role of bcl-2 protein is well known in some
forms of low grade lymphomas, including follicular lym-
phomas [14], its role in other cancers is under investiga-
tion. Studies could show the reactivity of tumor cells in
gastric carcinoma for bcl-2 with various frequencies
[14,50]. A higher frequency of apoptosis was shown in
gastric dysplasia rather than in coexisting gastric carci-
noma [50]. This observation is suggestive for a specific
role of Bcl-2 in gastric carcinoma development through
increasing cell life and imposing it to more genetic altera-
tions [50].
Although these observations are now far from practical
implementation in gastric cancer treatment, some reports
of successful application of apoptosis induction in gastric
cell lines are present [32,26].
Materials and methods
Paraffin blocks of 38 cases with gastric carcinoma operated
on between 11th March 1999 and 5th September 2003 were
collected from the archive of the Pathology Laboratory of
the Afzalipour Hospital. Representative tumor blocks were
selected for immunohistochemistry. A paraffin block of a
case with a gastrointestinal stoma tumor (GIST) was used
for positive control. Immunohistochemistry was per-
formed by application of the Avidin-Biotin Complex
(ABC) method for CD117 and bcl-2. Both primary anti-
bodies and LSAB visualization kit were commercially avail-
able from DAKO, Copenhagen, Denmark. The heat –
induced method (HIER) was applied for antigen retrieval
by tris-EDTA buffer PH9. The primary antibody dilution
was set to 1/400 for CD117 and to 1/40 for bcl-2 respec-
tively. The deparaffinized and rehydrated slides were incu-
bated with the primary antibodies for 20 minutes, after
thorough washing with the secondary antibody for 10 min-
utes, with streptavidin for 10 minutes, and liquid Diami-
nobenzydine (DAB) for 5 minutes. Cases were grouped
positive if a dark brown reaction in the tumor cells was
noted.
Results
The complete list of the 38 cases is given in table 2. The
spectrum of the patients' age ranges from 23 to 88 years
(mean 56). The sex ratio (men/women) accounts to 1.7:1.
Twenty patients underwent a total gastrectomy, the others
were treated by subtotal gastrectomy. Six of the tumors
developed from the cardiac region (15%), additional six
tumors from the corpus area (15%), and 18 cases were
located in the antrum (47%). In 6 cases (15%) the tumor
extensively infiltrated the stomach, and a detailed loca-
Strong and diffuse cytoplasmic reactivity for bcl-2 in case 11 Figure 5
Strong and diffuse cytoplasmic reactivity for bcl-2 in case 11.
Immunohistochemical staining for CD117 shows strong dif- fuse positive reaction in control slide (GIST) Figure 4
Immunohistochemical staining for CD117 shows strong dif-
fuse positive reaction in control slide (GIST). Note absence 
of background staining in non-neoplastic elements at the top 
of image.Diagnostic Pathology 2006, 1:7 http://www.diagnosticpathology.org/content/1/1/7
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tion of the tumors could not be identified. One case orig-
inated from gastro-esophageal junction and another
single case infiltrated both the body and the cardia.
According to the Lauren classification 20 cases (52.6%)
were grouped into the intestinal type (figure 1) and 17
cases (44.7%) were grouped into the diffuse type (figure
2). One mucinous type was seen (2.7%). Within the
group of intestinal type tumors 8 cases were well, and 12
cases moderately or poorly differentiated. Most of the
patients were operated on in advanced tumor stages
showing only two cases at stage I (5.3%) and 3 cases at
stage II (7.9%). The advanced stages include 16 cases
(42.1%) at stage IIIA, 15 cases (39.4) at stage IIIB, and 2
cases (5.3%) in stage IV according to the rules of the
AJCC/UICC [43].
The CD117 IHC reaction was negative in all cases includ-
ing the normal surface and glandular epithelium, dysplas-
tic epithelial cells around the tumor, and the invasive
components of gastric carcinoma cells (figure 3) while
positive control (GIST) revealed strong and diffuse cyto-
plasmic reactivity (figure 4). The IHC staining for bcl-2
was also negative in all cases except for one case of a dif-
fuse gastric carcinoma (case no. 11) that showed a distrib-
uted strong cytoplasmatic reactivity (figure 5). In 5 cases a
scattered and weak cytoplasmatic reactivity was noted for
bcl-2, which was considered to be negative too.
Discussion
The mean age of gastric carcinoma cases in this study (56
years) is significantly lower than that of population based
incidence (70 years). Most of our cases had been operated
on in advanced tumor stages, and account to a percentage
of 86% in stage three and higher.
Obviously, a potential curative surgical and chemothera-
peutic treatment of such advanced, poorly differentiated,
and aggressive tumors is not possible. Therefore, new
therapeutic approaches should be searched for.
One potential regime could be the treatment with iman-
tinib, a substance that originally served for the inhibition
of the abl-bcr fusion gene product in chronic myeloge-
nous leukemia. It can also act as a kit tyrosine kinase
inhibitor, and, therefore, its expression has been analyzed
in GIST and a broad variety of other malignancies [34]. In
fact, some oncologists request kit IHC stains when they
are confronted with mesenchymal tumors in order to
potentially apply imatinib for treatment [34]. Surpris-
ingly, the CD117 expression in gastric carcinomas was not
clearly evident although it has been investigated in
numerous tumors, such as germ cell or melanocytic
malignancies. We could only evaluate one article that
describes an over expression of the CD117 gene in gastric
carcinoma cell cultures [18].
In our study, none of the studied 38 cases displayed a
CD117 expression immunohistochemically. Therefore, it
seems to be unlikely, that CD117 plays a remarkable role
in gastric carcinoma formation and progression. In addi-
tion, its potential application as a new target for therapeu-
tic strategies is questionable. This statement holds true,
even if more sensitive methods like fluorescent in situ
hybridization (FISH) may detect a CD117 expression in
gastric carcinoma tumor cells without corresponding IHC
results. Miettinen et al. have examined kit-positive angi-
osarcomas for kit mutations and could not detect any
abnormalities in the region typically mutated in GIST
[34]. Thus, a positive IHC reaction cannot imply the
application of anti kit drug regimes per se. On the other
hand, mutations of CD117 genes might be present in the
development of gastric carcinomas, and cannot be
excluded by our study, as the applied antibodies are only
directed against the "wild type" protein formation.
A similar situation was found for bcl-2 expression, which
could be demonstrated intra-cytoplasmatically in only
one case of a diffuse gastric carcinoma. Thus, the majority
of gastric carcinomas (if not all) are immunohistochemi-
cally negative for bcl-2. These results are in agreement
with the data reported by Wang and his colleagues. The
authors reported only 2 bcl-2 positive cases out of 30 gas-
tric carcinomas [47]. Fricke et al. reported a higher per-
centage of immunohistochemical reactivity (5/24) for bcl-
2 in a study performed on 24 cases of diffuse type gastric
carcinomas [15]. All of these cases were concurrently pos-
itively associated with E-cadherin mutations [15]. But
there are increasing reports on Bcl-2 reactivity in gastric
cancer with much higher frequency (11, 14). Chen and
colleagues reported 80.56% of immunohistochemical
reactivity of gastric cancer cells to bcl-2 protein which was
irrespective to tumor location, histologic type of cancer,
and lymph node metastasis status (11). A report from Bra-
zil shows 45% of IHC reactivity of tumor cells for bcl-2
protein (14). In both studies different types of antibody
were used. In Chen study a specific method of assessment
was considered for quantitative and qualitative evaluation
of IHC reaction for bcl-2 (11). Considering low frequency
of reactivity of gastric cancer cells in many reports includ-
ing that of us, it seems to be rational to perform a large
scale and inter-institutional study using specific measure-
ments as electronic measurements to verify the exact rate
of bcl-2 reactivity in gastric cancer.
Conclusion
Summarizing these data and including our own results
the expression of CD117 in gastric carcinoma seems to be
a very unlikely event and can not practically considered as
a potential target of therapy. The expression of bcl-2 in
gastric carcinoma seems to be quite rare and currently its
clinical significance is unclear. But further large studiesDiagnostic Pathology 2006, 1:7 http://www.diagnosticpathology.org/content/1/1/7
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needed to perform in order to verify the exact rate of bcl-
2 reactivity in gastric carcinoma.
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